Trevi治疗学公司的库存在试验结果良好后猛增40%以上,分析师提高了目标。 Trevi Therapeutics' stock soars over 40% after positive trial results, with analysts raising targets.

HC Wainwright将其Trevi治疗药品库存的价格目标从7.50美元提高到12.50美元, HC Wainwright raised its price target for Trevi Therapeutics stock from $7.50 to $12.50, maintaining a "buy" rating. 该公司的重点是发展慢性咳嗽治疗Haduvio,在报告第2阶段的试验结果显示咳嗽频率显著下降后,其库存猛增40%以上。 The company, focused on developing the chronic cough treatment Haduvio, saw its stock surge over 40% after reporting positive phase 2a trial results showing a significant reduction in cough frequency. Trevi Therapeutics 的股价创下 52 周新高，此前 Raymond James 将其评级上调至“强烈买入”，目标价为 29.00 美元。 Trevi Therapeutics' stock hit a new 52-week high after Raymond James upgraded its rating to "strong-buy" with a target of $29.00.